DNA vaccines to target the cancer testis antigen PASD1 in human multiple myeloma

Leukemia

Volumn 24, Issue 11, 2010, Pages 1951-1959

  Joseph Pietras, D ^a   Gao, Y ^a   Zojer, N ^a   Ait Tahar, K ^b   Banham, A H ^b   Pulford, K ^b   Rice, J ^a   Savelyeva, N ^a   Sahota, S S ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

cancer testis antigen; DNA vaccines; immunotherapy; multiple myeloma; PASD1

Indexed keywords

CANCER TESTIS ANTIGEN; DNA VACCINE; EPITOPE; HLA A2 ANTIGEN; PROTEIN PASD 1; TETANUS TOXIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; DRUG TARGETING; ELECTROPORATION; FUSION GENE; GENE SEQUENCE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 78149466753     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.196     Document Type: Article

References (30)

1. Sirohi B, Powles R. Multiple myeloma. Lancet 2004; 363: 875-887.
2. Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008; 111: 2962-2972.
3. Rice J, King CA, Spellerberg MB, Fairweather N, Stevenson FK. Manipulation of pathogen-derived genes to influence antigen presentation via DNA vaccines. Vaccine 1999; 17: 3030-3038.
4. Spellerberg MB, Zhu D, Thompsett A, King CA, Hamblin TJ, Stevenson FK. DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C. J Immunol 1997; 159: 1885-1892.
5. King CA, Spellerberg MB, Zhu D, Rice J, Sahota SS, Thompsett AR et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 1998; 4: 1281-1286.
6. Rice J, Buchan S, Dewchand H, Simpson E, Stevenson FK. DNA fusion vaccines induce targeted epitope-specific CTLs against minor histocompatibility antigens from a normal or tolerized repertoire. J Immunol 2004; 173: 4492-4499.
7. Rice J, Dossett ML, Ohlen C, Buchan SL, Kendall TJ, Dunn SN et al. DNA fusion gene vaccination mobilizes effective anti-leukemic cytotoxic T lymphocytes from a tolerized repertoire. Eur J Immunol 2008; 38: 2118-2130.
8. Rice J, Elliott T, Buchan S, Stevenson FK. DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines. J Immunol 2001; 167: 1558-1565.
9. Low L, Mander A, McCann K, Dearnaley D, Tjelle T, Mathiesen I et al. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther 2009; 20: 1269-1278.
10. Chen YT, Gure AO, Tsang S, Stockert E, Jager E, Knuth A et al. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci USA 1998; 95: 6919-6923.
11. Condomines M, Hose D, Reme T, Requirand G, Hundemer M, Schoenhals M et al. Gene expression profiling and real-time PCR analyses identify novel potential cancer-testis antigens in multiple myeloma. J Immunol 2009; 183: 832-840.
12. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002; 188: 22-32.
13. Suri A. Cancer testis antigensFtheir importance in immunother-apy and in the early detection of cancer. Expert Opin Biol Ther 2006; 6: 379-389.
14. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 2004; 4: 1.
15. Goodyear OC, Pratt G, McLarnon A, Cook M, Piper K, Moss P. Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma. Blood 2008; 112: 3362-3372.
16. Sahota SS, Goonewardena CM, Cooper CD, Liggins AP, Ait-Tahar K, Zojer N et al. PASD1 is a potential multiple myeloma-associated antigen. Blood 2006; 108: 3953-3955.
17. Liggins AP, Brown PJ, Asker K, Pulford K, Banham AH. A novel diffuse large B-cell lymphoma-associated cancer testis antigen encoding a PAS domain protein. Br J Cancer 2004; 91: 141-149.
18. Cooper CD, Liggins AP, Ait-Tahar K, Roncador G, Banham AH, Pulford K. PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy. Leukemia 2006; 20: 2172-2174.
19. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 1997; 185: 2043-2051.
20. Ait-Tahar K, Liggins AP, Collins GP, Campbell A, Barnardo M, Lawrie C et al. Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma. Br J Haematol 2009; 146: 396-407.
21. Buchan S, Gronevik E, Mathiesen I, King CA, Stevenson FK, Rice J. Electroporation as a 'prime/boost' strategy for naked DNA vaccination against a tumor antigen. J Immunol 2005; 174: 6292-6298.
22. Dhodapkar MV, Osman K, Teruya-Feldstein J, Filippa D, Hedvat CV, Iversen K et al. Expression of cancer/testis antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammo-pathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun 2003; 3: 9.
23. Radcliffe JN, Roddick JS, Friedmann PS, Stevenson FK, Third-borough SM. Prime-boost with alternating DNA vaccines designed to engage different antigen presentation pathways generates high frequencies of peptide-specific CD8+ T cells. J Immunol 2006; 177: 6626-6633.
24. Palmowski MJ, Choi EM, Hermans IF, Gilbert SC, Chen JL, Gileadi U et al. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol 2002; 168: 4391-4398.
25. Stevenson FK, Ottensmeier CH, Rice J. DNA vaccines against cancer come of age. Curr Opin Immunol 2010; 22: 264-270.
26. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113: 5412-5417.
27. Spisek R, Kukreja A, Chen LC, Matthews P, Mazumder A, Vesole D et al. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammo-pathy. J Exp Med 2007; 204: 831-840.
28. Lendvai N, Gnjatic S, Ritter E, Mangone M, Austin W, Reyner K et al. Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients. Cancer Immun 2010; 10: 4.
29. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089-3094.
30. Administration. UFaD. FDA labelling informationFProvenge. FDA website (online), http://www.fda.gov/downloads/Biologics-BloodVaccines/ CellularGeneTherapyProducts/ApprovedProducts/UCM210031.pdf, 2010.